Plus Therapeutics (NASDAQ:CNSY) Announces Earnings Results

Plus Therapeutics (NASDAQ:CNSY) released its earnings results on Friday. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.35), Zacks reports. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%.

Plus Therapeutics Stock Down 0.5%

Shares of NASDAQ:CNSY traded down $0.02 during midday trading on Friday, hitting $3.68. The company had a trading volume of 95,231 shares, compared to its average volume of 306,130. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42. The firm has a market capitalization of $25.33 million, a P/E ratio of -1.60 and a beta of 1.42.

Analyst Upgrades and Downgrades

CNSY has been the topic of several recent research reports. Weiss Ratings began coverage on Plus Therapeutics in a report on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Zacks Research cut Plus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. Two analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.